Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20425535 | 1.00 | SRC (0.42) | SRCADAMTS4ALDH1A1GAAKMT2A | |
| SCHEMBL20299946 | 0.84 | SRC (0.41) | SRCADAMTS4ALDH1A1GAAKMT2A | |
| SCHEMBL3666840 | 0.76 | SRC (0.47) | SRCALDH1A1GAAKMT2ATDP1 | |
| SCHEMBL26121555 | 0.74 | CTSS (0.44) | APP | |
| SCHEMBL21243762 | 0.74 | CTSS (0.44) | APP | |
| SCHEMBL3112337 | 0.73 | TDP1 (0.44) | SRCALDH1A1GAAKMT2ATDP1 | |
| SCHEMBL189878 | 0.73 | TDP1 (0.44) | SRCALDH1A1GAAKMT2ATDP1 | |
| SCHEMBL28688103 | 0.73 | TDP1 (0.44) | SRCALDH1A1GAAKMT2ATDP1 | |
| Methane SCHEMBL20292606 | 0.72 | TDP1 (0.43) | SRCALDH1A1GAAKMT2ATDP1 | |
| Iodide SCHEMBL27294834 | 0.72 | TDP1 (0.43) | SRCALDH1A1GAAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5917087-A | IODINATION OF TYROSINE, FOLLOWED BY REMOVAL OF EXCESS OF IODINE, ACETYLATION OF INTERMEDIATE WITH ACETIC ANHYDRIDE AND A BASE, ESTERIFICATION OF THE FORMED PRODUCT, OXIDATITIVE COUPLING IN AIR WITH MANGANESE SALT, BORIC ACID AND AMINE | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-06-29 | — | — | US | claimed |
| EP-0920411-A1 | DIAGNOSTIC IMAGING CONTRAST AGENT WITH IMPROVED IN-SERUM-RELAXIVITY | BRACCO S.p.A. (IT) | 1999-06-09 | — | — | EP | claimed |
| EP-0828721-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1998005626-A1 | DIAGNOSTIC IMAGING CONTRAST AGENT WITH IMPROVED IN-SERUM-RELAXIVITY | BRACCO S.P.A. (IT) | 1998-02-12 | — | — | WO | claimed |
| US-20260115330-A1 | RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260041799-A1 | HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250249130-A1 | RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| CN-111655243-A | Method for modulating dopamine in human nervous system disorders | 乔纳森·萨克纳-伯恩斯坦 | 2020-09-11 | — | — | CN | disclosed |
| WO-2018140799-A2 | NEUROTROPHIN MUTANTS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | HORACIO URI SARAGOVI (CA) | 2018-08-02 | — | — | WO | disclosed |
| EP-3024326-A1 | NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM | Azico Biophore India Private Limited (IN) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015011573-A1 | NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM | AZICO PHARMACEUTICALS PRIVATE LIMITED (IN) | 2015-01-29 | — | — | WO | disclosed |
| WO-1999045967-A1 | MANGANESE CHELATES WITH HIGH RELAXIVITY IN SERUM | BRACCO S.P.A. (IT) | 1999-09-16 | — | — | WO | disclosed |
| US-5917087-A | IODINATION OF TYROSINE, FOLLOWED BY REMOVAL OF EXCESS OF IODINE, ACETYLATION OF INTERMEDIATE WITH ACETIC ANHYDRIDE AND A BASE, ESTERIFICATION OF THE FORMED PRODUCT, OXIDATITIVE COUPLING IN AIR WITH MANGANESE SALT, BORIC ACID AND AMINE | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-06-29 | — | — | US | disclosed |
| EP-0920411-A1 | DIAGNOSTIC IMAGING CONTRAST AGENT WITH IMPROVED IN-SERUM-RELAXIVITY | BRACCO S.p.A. (IT) | 1999-06-09 | — | — | EP | disclosed |
| US-5780509-A | Compound bearing two, 2,6-diiodophenol-4-YL groups and diagnostic drug for iodine allergy | MUROMACHI KAGAKU KOGYO KAISHA, LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0839880-A1 | Bleed alleviation in ink jet inks using acids containing a basic functional group | Hewlett-Packard Company (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0828721-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1998005626-A1 | DIAGNOSTIC IMAGING CONTRAST AGENT WITH IMPROVED IN-SERUM-RELAXIVITY | BRACCO S.P.A. (IT) | 1998-02-12 | — | — | WO | disclosed |
| US-5679143-A | Bleed alleviation in ink jet inks using acids containing a basic functional group | HEWLETT-PACKARD COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115330-A1 | RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS | KLK3, BRDT, BPHL | SRC 449/4885ADAMTS4 1719/4885ALDH1A1 540/4885 |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | IAPP, NPPA, ARG1 | SRC 865/4885ADAMTS4 2730/4885ALDH1A1 4110/4885 |
| US-20260041799-A1 | HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME | PAM, CRYAA, COL1A1 | SRC 2003/4885ADAMTS4 1415/4885ALDH1A1 306/4885 |
| US-20250249130-A1 | RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS | IAPP, IGFBP6, NPPA | SRC 885/4885ADAMTS4 262/4885ALDH1A1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.